1. Lacey SW. Cholera: calamitous past, ominous future. Clin
Infect Dis. 1995;20(5):1409-1419.
2. Carpenter CC. The treatment of cholera: clinical science
at the bedside. J Infect Dis. 1992;166(1):2-14.
3. Fukuda JM, Yi A, Chaparro L, Campos M, Chea E. Clinical characteristics
and risk factors for Vibrio cholerae infection
in children. J Pediatr. 1995;126(6):882-886.
4. Gil AI, Lanata CF, Butron B, Gabilondo A, Molina M, Bravo
N. Incidence of Vibrio cholerae O1 diarrhea in
children at the onset of cholera epidemic in periurban Lima, Peru. Pediatr
Infect Dis J. 1996;15(5):415-418.
5. Bhattacharya MK, Dutta D, Bhattacharya SK, et al. Association
of a disease approximating cholera caused by Vibrio cholerae of
serogroups other than O1 and O139. Epidemiol Infect. 1998;120(1):1-5.
6. Savarino SJ. A legacy in 20th-century medicine: Robert Allan
Phillips and the taming of cholera. Clin Infect Dis. 2002;35(6):713-720.
7. Singh J, Bora D, Sachdeva V, Sharma RS, Verghese T. Vibrio
cholerae O1 and O139 in less than five years old children hospitalised
for watery diarrhoea in Delhi, 1993. J Diarrhoeal Dis Res. 1997;15(1):3-6.
8. Singh J, Sachdeva V, Bhatia R, Bora D, Jain DC, Sokhey J.
Endemic cholera in Delhi, 1995: analysis of data from a sentinel
centre. J Diarrhoeal Dis Res. 1998;16(2):66-73.
9. Centers for Disease Control and Prevention. Summary of Notifiable
Diseases—United States, 2005. MMWR. 2007;54(53):1-92.
10. Two cases of toxigenic Vibrio cholerae O1 infection
after Hurricanes Katrina and Rita—Louisiana, October 2005. MMWR. 2006;55(2):31-32.
11. Colwell RR. Infectious disease and environment: cholera
as a paradigm for waterborne disease. Int Microbiol. 2004;7(4):285-289.
12. Steinberg EB, Greene KD, Bopp CA, Cameron DN, Wells JG,
Mintz ED. Cholera in the United States, 1995–2000: trends
at the end of the twentieth century. J Infect Dis. 2001;184(6):799-802.
13. Hlady WG, Klontz KC. The epidemiology of Vibrio infections
in Florida, 1981–1993. J Infect Dis. 1996;173(5):1176-1183.
14. Update: Vibrio cholerae O1—Western
Hemisphere, 1991–1994, and V cholerae O139—Asia,
1994. MMWR. 1995;44(11):215-219.
15. Guerrant RL, Steiner TS, Lima AA, Bobak DA. How intestinal
bacteria cause disease. J Infect Dis. 1999;179(suppl
2):S331-S337.
16. Swerdlow DL, Mintz ED, Rodriguez M, et al. Severe life-threatening
cholera associated with blood group O in Peru: implications for
the Latin American epidemic. J Infect Dis. 1994;170(2): 468-472.
17. Taylor DN, Cardenas V, Sanchez JL, et al. Two-year study
of the protective efficacy of the oral whole cell plus recombinant
B subunit cholera vaccine in Peru. J Infect Dis. 2000;181(5):1667-1673.
18. Sanchez JL, Vasquez B, Begue RE, et al. Protective efficacy
of oral whole-cell/recombinant-B-subunit cholera vaccine
in Peruvian military recruits. Lancet. 1994;344(8932):1273-1276.
19. Lucas ME, Deen JL, von Seidlein L, et al. Effectiveness
of mass oral cholera vaccination in Beira, Mozambique. N
Engl J Med. 2005;352(8):757-767.
20. Simanjuntak CH, O’Hanley P, Punjabi NH, et al.
Safety, immunogenicity, and transmissibility of single-dose live
oral cholera vaccine strain CVD 103-HgR in 24- to 59-month-old Indonesian
children. J Infect Dis. 1993;168(5):1169-1176.
21. Tacket CO, Cohen MB, Wasserman SS, et al. Randomized, double-blind,
placebo-controlled, multicentered trial of the efficacy of a single dose
of live oral cholera vaccine CVD 103-HgR in preventing cholera following
challenge with Vibrio cholerae O1 El tor inaba
three months after vaccination. Infect Immun. 1999;67(12):6341-6345.
22. Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial
of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta,
Indonesia, a cholera-endemic area. Vaccine. 2000;18(22):2399-2410.
23. American Academy of Pediatrics. Cholera. In: Pickering L,
ed. Red Book: 2006 Report of the Committee on Infectious
Diseases. 27 ed. Elk Grove Village, IL: American Academy
of Pediatrics; 2006:725-727.
24. Levine MM. Oral vaccines against cholera: lessons from Vietnam
and elsewhere.
Lancet. 1997; 349(9047):220-221.
[PubMed: 9014902]
25. Levine MM, Kaper JB, Herrington D, et al. Safety, immunogenicity,
and efficacy of recombinant live oral cholera vaccines, CVD 103
and CVD 103-HgR. Lancet. 1988;2(8609):467-470.